echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Hutchison Pharma enters into an agreement to sell non-core non-prescription drug joint ventures for US$169 million

    Hutchison Pharma enters into an agreement to sell non-core non-prescription drug joint ventures for US$169 million

    • Last Update: 2021-05-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 24, Hutchison Medicine announced that it had reached a US$169 million transaction agreement with GL Mountrose Investment Two Limited, which is controlled and managed by Telford Capital.


    Hutchison Medicine will receive a total of approximately US$169 million in cash from this transaction, which is equivalent to approximately 22 times the adjusted net profit of Baiyunshan Hutchison Medicine’s adjusted net profit of US$7.


    Telford Capital must pay a deposit of US$15.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.